Page last updated: 2024-12-11

3,3'-di-o-methylellagic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,3'-di-O-methylellagic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5488919
CHEMBL ID487203
SCHEMBL ID941032
MeSH IDM0143938

Synonyms (27)

Synonym
3,8-di-o-methylellagic acid
OPREA1_264874
NCGC00160203-01
CHEMBL487203 ,
3,3'-di-o-methylellagic acid
(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2,7-dihydroxy-3,8-dimethoxy-
2239-88-5
SCHEMBL941032
3,3'-di-o-methylellagicacid
[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione,2,7-dihydroxy-3,8-dimethoxy-
Q-100921
FT-0698044
DTXSID20176918
AKOS032948447
6,13-dihydroxy-7,14-dimethoxy-2,9-dioxatetracyclo[6.6.2.0^{4,16.0^{11,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
F17672
6,13-dihydroxy-7,14-dimethoxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
mfcd01083342
3,3-di-o-methylellagic acid
AS-6190
HY-N1969
CS-0018289
A878545
bdbm50521707
CAA23988
PD125617
3,8-di-o-methylellagicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.85280.003245.467312,589.2998AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.56230.004023.8416100.0000AID485290
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency7.07950.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency1.97830.125919.1169125.8920AID2549; AID504841
endonuclease IVEscherichia coliPotency11.22020.707912.432431.6228AID2565
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency10.00000.011212.4002100.0000AID1030
Bloom syndrome protein isoform 1Homo sapiens (human)Potency14.12540.540617.639296.1227AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency5.01190.001815.663839.8107AID894
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency0.44670.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.44670.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency0.44670.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency0.44670.01418.602439.8107AID2572
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)IC50 (µMol)100.00000.51001.64373.1200AID1588066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
protein O-linked glycosylationPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
O-glycan processingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein O-linked glycosylation via serinePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein O-linked glycosylation via threoninePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein maturationPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
polypeptide N-acetylgalactosaminyltransferase activityPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
manganese ion bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
carbohydrate bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
extracellular regionPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
endoplasmic reticulum membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi stackPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi cisterna membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
perinuclear region of cytoplasmPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1588066Inhibition of catalytic activity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293T cells and using 5-FAM labelled-EA2 peptide as substrate incubated for 30 mins by HPLC-based enzyme assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Inhibition of polypeptide N-acetyl-α-galactosaminyltransferases is an underlying mechanism of dietary polyphenols preventing colorectal tumorigenesis.
AID333820Antioxidant activity against LDL-susceptible to oxidation in New Zealand White rabbit plasma assessed as increase in conjugated diene formation at 25 ug/mL after 30 mins2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID333822Antioxidant activity against lipid peroxidation in Wistar rat brain assessed as inhibition of malondialdehyde release at 50 ug/mL by thiobarbituric acid method relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID333821Antioxidant activity against LDL-susceptible to oxidation in New Zealand White rabbit plasma assessed as increase in conjugated diene formation at 12.5 ug/mL after 30 mins2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID333823Antioxidant activity against lipid peroxidation in Wistar rat brain assessed as inhibition of malondialdehyde release at 25 ug/mL by thiobarbituric acid method relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID333819Antioxidant activity against LDL-susceptible to oxidation in New Zealand White rabbit plasma assessed as increase in conjugated diene formation at 50 ug/mL after 30 mins2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID1494599Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Anticomplement compounds from Polygonum chinense.
AID333824Antioxidant activity against lipid peroxidation in Wistar rat brain assessed as inhibition of malondialdehyde release at 12.5 ug/mL by thiobarbituric acid method relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
Bioactive compounds from the seeds of Punica granatum (pomegranate).
AID1494600Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
Anticomplement compounds from Polygonum chinense.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's5 (41.67)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]